MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1055-9965.epi-25-2068

Медицинская библиотека · Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026

Integrating In Situ Immune Expression Landscape with Gene Expression-Based Subtyping to Characterize Breast Cancer Heterogeneity.

Abubakar Mustapha, Koka Hela, Lee Priscilla Ming Yi, Tang Hiu Yu Natalie, Lawrence Scott, Mutreja Karun, Wang Feng, Wu Cherry, Tsang Koon-Ho, Tsoi Yee-Kei, Chan W C, Law Sze Hong, Hung Ray Ka Wai, Tse Gary M K, Jones Kristine, Vogt Aurelie, Brown Maria, Hicks Belynda D, Wang Difei, Zhu Bin, Tse Lap Ah, Yang Xiaohong R

СтатьяПеревод в очереди

Аннотация

BACKGROUND

We previously identified three clinically relevant immune [i.e., low-tumor-infiltrating lymphocyte (TIL), high-TIL, and high-interferon-stimulated gene (ISG)] subtypes of luminal breast cancer using RNA sequencing in a cohort of women from Hong Kong. In this study, we evaluated whether standard, in situ immunohistochemistry (IHC), a more clinically accessible approach, could capture similar immune heterogeneity across intrinsic (PAM50) subtypes.

METHODS

In 148 patients with invasive breast cancer, we performed dual IHC staining for eight markers (CD3, CD8, CD20, FOXP3, CD68, CD163, PDL1, and IDO1) with pan-cytokeratin and quantified immune-positive cells in stromal regions by digital image analysis.

RESULTS

IHC marker expression strongly correlated with gene expression-based immune and intrinsic subtypes. Compared with luminal tumors classified as low-TIL, high-TIL tumors showed higher levels of CD3, CD8, CD20, PDL1, and IDO1. Similarly, high-ISG tumors expressed higher CD3, CD8, CD20, PDL1, and IDO1 than low-TIL tumors but were distinguished from high-TIL tumors by elevated CD163. Immune marker expression was generally higher in HER2-enriched and basal-like tumors than in luminal A and B tumors, though substantial variability existed within each subtype. Luminal B tumors expressed higher levels of CD3, CD8, CD20, and CD163 compared with luminal A tumors. Notably, immune infiltration was more strongly aligned with aggressive tumor features such as high grade, risk of recurrence scores, and TP53 mutations than with estrogen receptor/progesterone receptor expression.

CONCLUSIONS

These findings confirm that subsets of luminal tumors harbor inflamed or macrophage-driven immune microenvironments.

IMPACT: Parsimonious IHC panels can perform immune classification, supporting their potential utility in refining subtype stratification and informing clinical decision-making, particularly in resource-limited settings.

Для цитирования: Abubakar Mustapha, Koka Hela, Lee Priscilla Ming Yi, Tang Hiu Yu Natalie, Lawrence Scott, Mutreja Karun, Wang Feng, Wu Cherry, Tsang Koon-Ho, Tsoi Yee-Kei, Chan W C, Law Sze Hong, Hung Ray Ka Wai, Tse Gary M K, Jones Kristine, Vogt Aurelie, Brown Maria, Hicks Belynda D, Wang Difei, Zhu Bin, Tse Lap Ah, Yang Xiaohong R. Integrating In Situ Immune Expression Landscape with Gene Expression-Based Subtyping to Characterize Breast Cancer Heterogeneity.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2026. DOI: 10.1158/1055-9965.epi-25-2068.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.